CN101805328A - 埃坡霉素衍生物 - Google Patents

埃坡霉素衍生物 Download PDF

Info

Publication number
CN101805328A
CN101805328A CN201010150615A CN201010150615A CN101805328A CN 101805328 A CN101805328 A CN 101805328A CN 201010150615 A CN201010150615 A CN 201010150615A CN 201010150615 A CN201010150615 A CN 201010150615A CN 101805328 A CN101805328 A CN 101805328A
Authority
CN
China
Prior art keywords
solution
compound
diketone
oxa
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201010150615A
Other languages
English (en)
Chinese (zh)
Inventor
K-H·阿尔特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101805328A publication Critical patent/CN101805328A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201010150615A 2004-03-16 2005-03-15 埃坡霉素衍生物 Pending CN101805328A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405898.8 2004-03-16
GBGB0405898.8A GB0405898D0 (en) 2004-03-16 2004-03-16 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800069311A Division CN1926133B (zh) 2004-03-16 2005-03-15 埃坡霉素衍生物

Publications (1)

Publication Number Publication Date
CN101805328A true CN101805328A (zh) 2010-08-18

Family

ID=32117793

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201010150615A Pending CN101805328A (zh) 2004-03-16 2005-03-15 埃坡霉素衍生物
CN2005800069311A Expired - Fee Related CN1926133B (zh) 2004-03-16 2005-03-15 埃坡霉素衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2005800069311A Expired - Fee Related CN1926133B (zh) 2004-03-16 2005-03-15 埃坡霉素衍生物

Country Status (11)

Country Link
US (2) US7825141B2 (enExample)
EP (3) EP1730138A1 (enExample)
JP (1) JP2007529455A (enExample)
KR (1) KR20070006773A (enExample)
CN (2) CN101805328A (enExample)
AU (1) AU2005223325B2 (enExample)
BR (1) BRPI0508874A (enExample)
CA (1) CA2556915A1 (enExample)
GB (1) GB0405898D0 (enExample)
RU (1) RU2006136089A (enExample)
WO (1) WO2005090335A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007016046A1 (de) * 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
DE19751027A1 (de) 1996-11-20 1998-05-28 Degussa Arylsubstituierte aminoacylierte Phosphonsäuren und deren Halbester
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
IL135590A (en) 1997-12-04 2003-09-17 Bristol Myers Squibb Co Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19856128A1 (de) 1998-12-04 2000-06-15 Volkswagen Ag Verfahren und Einrichtung zum Lesen von Navigationsdaten
AU2795000A (en) * 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
BR0212107A (pt) 2001-08-23 2004-08-24 Novartis Ag Análogos da ciclopropil e da ciclobutil epotilona
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
AU2003266961A1 (en) 2002-08-02 2004-02-25 Novartis Ag Epothilone derivatives

Also Published As

Publication number Publication date
US20110009459A1 (en) 2011-01-13
CA2556915A1 (en) 2005-09-29
CN1926133B (zh) 2010-06-23
EP2213670A3 (en) 2010-11-24
BRPI0508874A (pt) 2007-09-04
EP2301940A1 (en) 2011-03-30
EP2213670A2 (en) 2010-08-04
AU2005223325B2 (en) 2009-09-10
RU2006136089A (ru) 2008-04-27
WO2005090335A1 (en) 2005-09-29
US20080114040A1 (en) 2008-05-15
CN1926133A (zh) 2007-03-07
JP2007529455A (ja) 2007-10-25
GB0405898D0 (en) 2004-04-21
KR20070006773A (ko) 2007-01-11
US7825141B2 (en) 2010-11-02
EP1730138A1 (en) 2006-12-13
AU2005223325A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
JP5455913B2 (ja) ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
JP5227304B2 (ja) 新規なヒドロキサム酸誘導体
CN103003233B (zh) 新型异羟肟酸衍生物
JP4712702B2 (ja) 高増殖性疾患を処置するために有用な置換されたテトラヒドロベンゾチエノピリミジンアミン化合物
WO2024125600A1 (zh) 作为kras抑制剂的杂环化合物，及其制备和治疗用途
JP2002543171A (ja) 疾患治療としての新規なキノン
WO1998058909A1 (en) Vitamin d3 derivatives and remedies for inflammatory respiratory diseases prepared from the same
US20190330261A1 (en) Ligand for orphan nuclear receptor nur77 and uses thereof
WO2023125928A1 (zh) Menin抑制剂及其用途
JP2002511457A (ja) ７−ヘキサノイルタキソール（登録商標）及びその調製法
WO2019223548A1 (zh) 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN115403511B (zh) 荜茇酰胺类似物、药物组合物及其制备方法和应用
CN101805328A (zh) 埃坡霉素衍生物
WO2019228170A1 (zh) 八氢戊搭烯类化合物、其制备方法及其在医药学上的应用
JP5451628B2 (ja) プロテインホスファターゼ阻害剤
AU2003252540B2 (en) Novel macrocycles for the treatment of cancer
AU2015358284B2 (en) 4H-pyrido[1,2-a]pyrimidin-4-one compounds
CN1393438B (zh) 紫杉烷衍生物及其制法和用途
CN119569728B (zh) 吡啶并吡咯类衍生物及其在制备富亮氨酸重复激酶2抑制剂中的应用
KR20090095791A (ko) 신규한 베타 치환된 모리타-베일리스-힐만 유도체
HU208019B (en) Process for producing alkoxy-methyliden-epi-podofillotoxin-glucosides and pharmaceutical compositions containing them
CN107325030A (zh) 一类新型反式芪类抗肿瘤剂
WO2025021181A1 (zh) 取代的吡咯啉酮化合物
AU2014327311A1 (en) Compounds useful in the treatment of neoplastic diseases
KR20090063771A (ko) 신규한 베타 치환된 모리타-베일리스-힐만 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100818